CD59 but not DAF deficiency accelerates atherosclerosis in female ApoE knockout mice

Molecular Immunology

Volumn 46, Issue 8-9, 2009, Pages 1702-1709

  An, Guipeng ^a,c   Miwa, Takashi ^a   Song, Wen Liang ^a   Lawson, John A ^a   Rader, Daniel J ^a,b   Zhang, Yun ^c   Song, Wen Chao ^a  

^a Institute for Translational Medicine   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BEIJING HOSPITAL   (China)

Author keywords

ApoE; Atherosclerosis; CD59; Complement; DAF

Indexed keywords

APOLIPOPROTEIN E; CD59 ANTIGEN; COLLAGEN; COMPLEMENT MEMBRANE ATTACK COMPLEX; DECAY ACCELERATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS BREEDING; FEMALE; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD55; ANTIGENS, CD59; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHOLESTEROL; DISEASE PROGRESSION; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SEX CHARACTERISTICS; TIME FACTORS;

MURINAE; MUS;

EID: 64149125357     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2009.02.009     Document Type: Article

References (51)

1. Babaev V.R., Patel M.B., Semenkovich C.F., Fazio S., and Linton M.F. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice. J Biol Chem 275 (2000) 26293-26299
2. Benzaquen L.R., Nicholson-Weller A., and Halperin J.A. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 179 (1994) 985-992
3. Bhakdi S., Torzewski M., Klouche M., and Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 19 (1999) 2348-2354
4. Bhatia V.K., Yun S., Leung V., Grimsditch D.C., Benson G.M., Botto M.B., Boyle J.J., and Haskard D.O. Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice. Am J Pathol 170 (2007) 416-426
5. Buono C., Come C.E., Witztum J.L., Maguire G.F., Connelly P.W., Carroll M., and Lichtman A.H. Influence of C3 deficiency on atherosclerosis. Circulation 105 (2002) 3025-3031
6. Halperin J.A., Taratuska A., and Nicholson-Weller A. Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest 91 (1993) 1974-1978
7. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
8. Kim D.D., Miwa T., Kimura Y., Schwendener R.A., van Lookeren Campagne M., and Song W.C. Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg. Blood 112 (2008) 1109-1119
9. Kim D.D., Miwa T., and Song W.C. Retrovirus-mediated over-expression of decay-accelerating factor rescues Crry-deficient erythrocytes from acute alternative pathway complement attack. J Immunol 177 (2006) 5558-5566
10. Li S.H., Szmitko P.E., Weisel R.D., Wang C.H., Fedak P.W., Li R.K., Mickle D.A., and Verma S. C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation 109 (2004) 833-836
11. Liu J., Miwa T., Hilliard B., Chen Y., Lambris J.D., Wells A.D., and Song W.C. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 201 (2005) 567-577 (Epub 2005 February 14)
12. Longhi M.P., Harris C.L., Morgan B.P., and Gallimore A. Holding T cells in check--a new role for complement regulators?. Trends Immunol 27 (2006) 102-108
13. Longhi M.P., Sivasankar B., Omidvar N., Morgan B.P., and Gallimore A. Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner. J Immunol 175 (2005) 7098-7102
14. Lublin D.M., and Atkinson J.P. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 7 (1989) 35-58
15. Mackness B., Hunt R., Durrington P.N., and Mackness M.I. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 17 (1997) 1233-1238
16. Mason J.C., Ahmed Z., Mankoff R., Lidington E.A., Ahmad S., Bhatia V., Kinderlerer A., Randi A.M., and Haskard D.O. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res 91 (2002) 696-703
17. Miwa T., Maldonado M.A., Zhou L., Sun X., Luo H.Y., Cai D., Werth V.P., Madaio M.P., Eisenberg R.A., and Song W.C. Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. Am J Pathol 161 (2002) 1077-1086
18. Miwa T., Zhou L., Hilliard B., Molina H., and Song W.C. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack. Blood 99 (2002) 3707-3716
19. Molina H., Miwa T., Zhou L., Hilliard B., Mastellos D., Maldonado M.A., Lambris J.D., and Song W.C. Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Decay-accelerating factor. Blood 100 (2002) 4544-4549 (Epub 2002 August 1)
20. Mollnes T.E., Song W.C., and Lambris J.D. Complement in inflammatory tissue damage and disease. Trends Immunol 23 (2002) 61-64
21. Morgan B.P., van den Berg C.W., Davies E.V., Hallett M.B., and Horejsi V. Cross-linking of CD59 and of other glycosyl phosphatidylinositol-anchored molecules on neutrophils triggers cell activation via tyrosine kinase. Eur J Immunol 23 (1993) 2841-2850
22. Murray E.W., and Robbins S.M. Antibody cross-linking of the glycosylphosphatidylinositol-linked protein CD59 on hematopoietic cells induces signaling pathways resembling activation by complement. J Biol Chem 273 (1998) 25279-25284
23. Nicholson-Weller A., Burge J., Fearon D.T., Weller P.F., and Austen K.F. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 129 (1982) 184-189
24. Nicoletti A., Kaveri S., Caligiuri G., Bariety J., and Hansson G.K. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 102 (1998) 910-918
25. Niculescu F., and Rus H. Complement activation and atherosclerosis. Mol Immunol 36 (1999) 949-955
26. Niculescu F., and Rus H. The role of complement activation in atherosclerosis. Immunol Res 30 (2004) 73-80
27. Niculescu F., Rus H.G., and Vlaicu R. Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis 65 (1987) 1-11
28. Niculescu F., Rus H.G., and Vlaicu R. Decay-accelerating factor regulates complement-mediated damage in the human atherosclerotic wall. Immunol Lett 26 (1990) 17-23
29. Okada N., Harada R., Fujita T., and Okada H. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol 1 (1989) 205-208
30. Oksjoki R., Kovanen P.T., and Pentikainen M.O. Role of complement activation in atherosclerosis. Curr Opin Lipidol 14 (2003) 477-482
31. Patel S., Thelander E.M., Hernandez M., Montenegro J., Hassing H., Burton C., Mundt S., Hermanowski-Vosatka A., Wright S.D., Chao Y.S., and Detmers P.A. ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5. Biochem Biophys Res Commun 286 (2001) 164-170
32. Patrono C., and FitzGerald G.A. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 17 (1997) 2309-2315
33. Persson L., Boren J., Robertson A.K., Wallenius V., Hansson G.K., and Pekna M. Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E -/- low-density lipoprotein receptor -/- mice. Arterioscler Thromb Vasc Biol 24 (2004) 1062-1067
34. Pratico D., Iuliano L., Mauriello A., Spagnoli L., Lawson J.A., Rokach J., Maclouf J., Violi F., and FitzGerald G.A. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 100 (1997) 2028-2034
35. Rokach J., Khanapure S.P., Hwang S.W., Adiyaman M., Lawson J.A., and FitzGerald G.A. Nomenclature of isoprostanes: a proposal. Prostaglandins 54 (1997) 853-873
36. Rollins S.A., and Sims P.J. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 144 (1990) 3478-3483
37. Rudic R.D., Brinster D., Cheng Y., Fries S., Song W.L., Austin S., Coffman T.M., and FitzGerald G.A. COX-2-derived prostacyclin modulates vascular remodeling. Circ Res 96 (2005) 1240-1247
38. Schmiedt W., Kinscherf R., Deigner H.P., Kamencic H., Nauen O., Kilo J., Oelert H., Metz J., and Bhakdi S. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 18 (1998) 1790-1795
39. Seifert P.S., and Hansson G.K. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis 9 (1989) 802-811
40. Seifert P.S., and Hansson G.K. Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions. J Clin Invest 84 (1989) 597-604
41. Sogabe H., Nangaku M., Ishibashi Y., Wada T., Fujita T., Sun X., Miwa T., Madaio M.P., and Song W.C. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. J Immunol 167 (2001) 2791-2797
42. Song W.C., Sarrias M.R., and Lambris J.D. Complement and innate immunity. Immunopharmacology 49 (2000) 187-198
43. Song W.L., Lawson J.A., Wang M., Zou H., and FitzGerald G.A. Noninvasive assessment of the role of cyclooxygenases in cardiovascular health: a detailed HPLC/MS/MS method. Methods Enzymol 433 (2007) 51-72
44. Sun X., Funk C.D., Deng C., Sahu A., Lambris J.D., and Song W.C. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci U S A 96 (1999) 628-633
45. Tangirala R.K., Rubin E.M., and Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res 36 (1995) 2320-2328
46. Vlaicu R., Rus H.G., Niculescu F., and Cristea A. Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis 55 (1985) 35-50
47. Vlaicu R., Rus H.G., Niculescu F., and Cristea A. Quantitative determinations of immunoglobulins and complement components in human aortic atherosclerotic wall. Med Interne 23 (1985) 29-35
48. Walport M.J. Complement. First of two parts. N Engl J Med 344 (2001) 1058-1066
49. Walport M.J. Complement. Second of two parts. N Engl J Med 344 (2001) 1140-1144
50. Wang M., Lee E., Song W., Ricciotti E., Rader D.J., Lawson J.A., Pure E., and FitzGerald G.A. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation 117 (2008) 1302-1309
51. Yun S., Leung V.W., Botto M., Boyle J.J., and Haskard D.O. Brief report: accelerated atherosclerosis in low-density lipoprotein receptor-deficient mice lacking the membrane-bound complement regulator CD59. Arterioscler Thromb Vasc Biol 28 10 (2008) 1714-1716 Epub 2008, Jul 10